A detailed history of Wilshire Advisors LLC transactions in Allakos Inc. stock. As of the latest transaction made, Wilshire Advisors LLC holds 75,055 shares of ALLK stock, worth $97,571. This represents 0.02% of its overall portfolio holdings.

Number of Shares
75,055
Previous 75,055 -0.0%
Holding current value
$97,571
Previous $75,000 36.0%
% of portfolio
0.02%
Previous 0.04%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$2.13 - $5.55 $159,867 - $416,555
75,055 New
75,055 $170,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $110M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Wilshire Advisors LLC Portfolio

Follow Wilshire Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilshire Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilshire Advisors LLC with notifications on news.